# Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age

> **NCT02948127** · PHASE1 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 8 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** RSV LID cp ΔM2-2 Vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02948127
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09
- **Primary completion:** 2017-04-30
- **Final completion:** 2018-04-30
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2018-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02948127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02948127, "Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02948127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*